Fab’entech 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
FBR-002 / Fab’entech
NCT05279352: Safety and Pharmacokinetics of FBR-002 for the Treatment of Patients Hospitalized With COVID-19 in Need of Supplemental Oxygen and at Risk of Severe Outcome

Recruiting
2a
30
Europe
FBR-002, Placebo
Fab'entech
COVID-19
06/22
07/22
2021-002390-25: Safety and pharmacokinetics of FBR-002 for the treatment of patients hospitalized with COVID-19 need of supplemental oxygen and at risk of severe outcome

Not yet recruiting
2
30
Europe
FBR-002, FBR-002, Solution for infusion
Fab'entech, European Commission (Hera incubator - EPIC Crown-2 project)
COVID-19 in hospitalized patients in need of supplemental oxygen and at risk of severe outcome, COVID-19, Diseases [C] - Virus Diseases [C02]
 
 
2022-002724-12: Evaluation of the efficacy and safety of a polyclonal equine fragments immunotherapy (FBR-002) in participants with COVID-19 requiring supplemental oxygen in hospital and at risk of severe outcome

Not yet recruiting
2
285
Europe, RoW
FBR-002, FBR-002, Solution for infusion
Fab'entech, European Commission (Hera Incubator - EPIC Crown-2 project)
COVID-19 in hospitalized patients in need of supplemental oxygen and at risk of severe outcome, COVID-19, Diseases [C] - Virus Diseases [C02]
 
 

Download Options